Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

April 17th 2025

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Patient self reporting or intentional physical examinations by clinicians remain the main avenues by which suspected skin cancers are identified. | Image credit: anna.stasiia - stock.adobe.com
Novel Methods Could Reshape Skin Cancer Diagnostics

April 10th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com
Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

April 2nd 2025

Estrogen | Image credit: Debalina - stock.adobe.com
Estrogen Therapy May Increase Risk of 3 Skin Cancers

March 20th 2025

Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

March 14th 2025

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Igor Puzanov, MD, Jacobs School of Medicine and Biomedical Sciences and Roswell Park Comprehensive Cancer Center
September 12th 2022

Dr Igor Puzanov Discusses the State of Adjuvant Therapy for Advanced Melanoma

AJMC Staff
In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.
Image of clinical research
September 7th 2022

More Study Needed on Melanoma Risk From Methotrexate

Maggie L. Shaw
Quantifying the risk of malignant melanoma from methotrexate use proved difficult in this new study, with the authors calling for larger studies with longer follow-up to guide future practice in the space.
Image of skin cancer
August 31st 2022

Dermoscopy May Be More Accurate vs Incisional Biopsy for Melanoma Thickness

Maggie L. Shaw
In this new study, investigators searched for potential predictors of melanoma thickness, with implications for treatment decisions regarding biopsy and excision margins.
Sigrun Hallmeyer, MD
August 24th 2022

Dr Sigrun Hallmeyer Highlights Clinical Achievements and Barriers in Melanoma

AJMC Staff
In this interview with The American Journal of Managed Care®, Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and co-director of medical research at Advocate Aurora Health, in Illinois, touches on several important topics within the melanoma space.
Patient learning about skin cancer
August 17th 2022

Skin Cancer Knowledge Suboptimal Among Patients

Maggie L. Shaw
Adult patients from dermatology clinics affiliated with 2 Midwest universities were evaluated for their ability to differentiate skin cancer by sight and for their skin cancer knowledge.
Image of a slide under a microscope
August 13th 2022

Second Opinions Likely Influenced by Initial Dermatopathology Diagnosis

Maggie L. Shaw
This study investigated how an initial diagnosis influences delivery of second opinions concerning skin cancers, including the possibility of an incorrect diagnosis.
Image of a skin cancer cell
August 10th 2022

SLN Biopsy Promising for Long-term Metastatic Melanoma Control

Maggie L. Shaw
The usefulness of sentinel lymph node (SLN) biopsy was investigated among patients with melanoma and SLN metastases.
Image of a transplant operation
August 2nd 2022

Risk of Keratinocyte Carcinoma Increases With Pediatric Solid Organ Transplant

Maggie L. Shaw
This new study investigated keratinocyte carcinoma mortality and morbidity rates following pediatric solid organ transplant. Little is known on these associations in pediatric patients; more is known of these outcomes among adult patients.
Image of an exam for skin cancer
July 29th 2022

Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ

Maggie L. Shaw
This new study, conducted among persons living with melanoma in situ, investigated the possibility of identifying clinicopathological predictors of local recurrence.
Image of potential skin cancer
July 25th 2022

Reflectance Confocal Microscopy Improves Skin Cancer Diagnosis in New Trial

Maggie L. Shaw
This prospective study on reflectance confocal microscopy, a high-resolution and noninvasive form of imaging for skin cancer, investigated if the diagnostic method could improve accuracy results by 30% following dermoscopy.
Vernon Sondak MD
July 22nd 2022

Dr Vernon Sondak on BRAF Mutations in Metastatic Melanoma

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the brain or other sites.
Image of the word "melanoma"
July 21st 2022

Pediatric, Adolescent Melanoma Uptick Seen in Finland

Maggie L. Shaw
Although melanoma incidence has been reported in Europe overall for the past several decades, specific numbers on the cancer’s incidence in Finland, as well as disease trends, have remained unknown.
Image of an older man
July 16th 2022

Use of Local Skin Flaps May Lead to Reduced Risk of Scarring Following Mohs Surgery

Maggie L. Shaw
Three methods of cosmetic surgery—local skin flap, full thickness skin graft, and secondary intention—were evaluated for their scarring risk following Mohs microscopic surgery on the distal third of the nose.
Georgina V. Long, MBBS, PhD
July 14th 2022

KEYNOTE-716: First Data on DMFS Show Additional Pembrolizumab Benefit in Patients With Melanoma

Maggie L. Shaw
New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma.
Image of DNA under a microscope
July 12th 2022

Genetic Patterns, Targeted Therapy Resistance Link in Melanoma Explored in New Study

Jared Kaltwasser
The analysis could help investigators better understand why a subset of patients with advanced melanoma develops resistance or does not respond to targeted therapy.
Image of a dermatologist examining a patient's skin
July 7th 2022

High-risk Mohs Surgery Outcomes Superior to Historical Data for cSCC, Study Shows

Jared Kaltwasser
This new report suggests patients with high-risk cutaneous squamous cell carcinoma (cSCC) have improved odds when they undergo Mohs micrographic surgery.
Image of possible skin cancer
June 24th 2022

Adjuvant Pembrolizumab Shows Favorable Health-Related Quality-of-Life Results in Resected Melanoma

Rose McNulty
An interim analysis of the KEYNOTE-716 trial of adjuvant pembrolizumab supports its use in the adjuvant setting for patients with resected melanoma.
Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors
June 22nd 2022

Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors

Allison Inserro
The combination is the first and only therapy to be approved with a tumor-agnostic indication in both children and adults with solid tumors that have a BRAF V600E mutation, Novartis said late Wednesday.
Omid Hamid, MD
June 15th 2022

Dr Omid Hamid on Choosing Targeted Therapy in Advanced Melanoma

AJMC Staff
Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, spoke with The American Journal of Managed Care® (AJMC®) about evaluating therapy options for patients with advanced melanoma.
Early Study of Brain-Permeable BRAF Inhibitor Shows Positive Results
June 11th 2022

Early Study of Brain-Permeable BRAF Inhibitor Shows Positive Results

AJMC Staff
Brain metastasis from melanoma is particularly deadly and options are limited due to the difficulty of breaching the brain-blood barrier.
operating room
June 3rd 2022

Older Patients Receiving Mohs Surgery Typically Have Facial Tumors, Are High-Functioning

Jared Kaltwasser
Investigators also found patients in nursing homes tend to have larger tumors and may experience quality-of-life benefits from the procedure.
dna image
June 1st 2022

SLC25A13 Could Be Prognostic, Therapeutic Biomarker in Skin Cutaneous Melanoma

Jared Kaltwasser
The analysis suggests the marker could be used to screen patients for potential immunotherapy.
doctors in hospital
May 28th 2022

Researchers Establish, Validate Prognostic Model for Uveal Melanoma

Jaime Rosenberg
The model consists of 3 metabolism-related genes—carbonic anhydrase 12, acyl-CoA synthetase long-chain family member 3, and synaptojanin 2— that the researchers said could potentially be used as biomarkers and treatment targets in the disease.
Jeffrey Weber, MD, PhD
May 23rd 2022

Dr Jeffrey Weber on the Staging of Melanoma and Choosing Treatment Options

AJMC Staff
Medical oncologist Jeffrey S. Weber, MD, PhD, spoke with The American Journal of Managed Care® (AJMC®) about how treatment options have improved for more advanced melanoma cases and the role that genetic mutations play in choosing therapy.
image of skin cancer
May 22nd 2022

Skin Microenvironment Could Yield New Melanoma Treatment Options, Study Finds

Jared Kaltwasser
The microenvironment of the skin also helps explain why certain ethnicities appear to have a higher risk of melanoma.
injection
May 18th 2022

Real-World Analysis Explores Clinical Activity, Safety of PD-1 Inhibition in Advanced BCC

Rose McNulty
Locally advanced or metastatic basal cell carcinoma can be challenging to treat, but programmed death receptor 1 inhibition may hold potential as a tolerable, effective approach in patients of all ages.
graphic of melanoma
May 15th 2022

Apatinib Prompts Responses in Patients With Recurrent Melanoma

Jared Kaltwasser
The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.
Image of the word melanoma
May 13th 2022

Melanoma Prevalence, Mortality Mostly Stable Over the Past 30 Years

Jared Kaltwasser
Data from this new study suggest melanoma cases rose at a slower rate in lower-income countries, but the authors say that may be due to differences in case documentation.
Image of a skin cancer exam
May 9th 2022

Study Suggests Awareness Alone Will Not Solve Skin Cancer Overdiagnosis Issue

Jared Kaltwasser
More experienced dermatopathologists were less likely to see overdiagnosis as a significant public health problem, a new survey showed.
Image of researcher examining DNA
May 5th 2022

Investigation Yields Potential New Genetic Biomarker for Anti–PD-1 Success in Melanoma

Jared Kaltwasser
Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo